News Hub | News Direct

Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar

Quidel Corporation

With Lyme disease season emerging and the COVID-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. Titled "Solve the Great Imitators: Is it COVID-19, Tick-Borne Disease or the Flu?," the webinar will be conducted by Sean McCloy,* M.D., M.P.H., M.A., national thought leader and medical director at the Integrative Health Center of Maine in Portland where he practices family medicine with an expertise in Lyme disease. The free educational program, being held in collaboration with the Global Lyme Alliance, will take place at noon EDT. Registration is available at Quidel x GLA Lyme Webinar Registration. “Lyme disease is often misdiagnosed because its symptoms often mimic other conditions like the flu and many others. As we enter peak tick season, it is important to remind health care providers and others about the importance of screening their patients for Lyme disease,” says Sara Tyghter, director of education and outreach at Global Lyme Alliance. “The trio of acute COVID-19 infection, tick-borne disease and influenza infection all have very similar presentations and share the common symptoms of fever/chills, fatigue, muscle aches and headaches,” says Dr. McCloy. “That makes it both challenging and critical for health care professionals to properly distinguish one from the other so that they can correctly treat their patients for the corresponding ailment. During the webinar, we’ll discuss the often subtle differences in how these illnesses affect patients and will review diagnostic options that will help physicians make point-of-care decisions so that their patients can get timely treatment and feel better quickly.” As the weather heats up during spring and summer, McCloy says that it is particularly important to test for Lyme disease, which afflicts as many as 400,000 Americans each year and can lead to a number of serious life-threatening problems if not caught early. “Fortunately, new tools are now available to make it easier to test for Lyme disease quickly and accurately,” he says. “The best tool I have found and one which has revolutionized the speed and accuracy for diagnosing Lyme disease is the Sofia® 2 Lyme FIA test by Quidel.” The Sofia 2 Lyme test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. “Not having to wait days for test results allows clinicians to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative,” says McCloy. Among those expected to attend the free May 5 webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers and others interested in the subject. * Dr. McCloy receives an honorarium for conducting the webinar sponsored by Quidel. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Quidel Corporation Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

April 27, 2021 09:00 AM Eastern Daylight Time

SullivanCotter Welcomes New Information Security Officer Jeffery A. Peal

SullivanCotter

S ullivanCotter, the nation’s leading independent consulting firm in the assessment and development of total rewards programs, workforce solutions, and technology and data products for the health care industry and not-for-profit sector, is pleased to announce the addition of Jeffery A. Peal as its Information Security Officer. With over 20 years of cybersecurity and information technology experience, Jeff has a longstanding passion for providing business-enabled solutions while also managing risk and strengthening organizational security. His demonstrated ability to envision, lead and implement innovative IT programs helps to enhance security awareness, increase productivity, and mitigate risk and exposure. “Now more than ever, the not-for-profit and health care industry continues to transform its information security practices at a rapid pace. As our clients look to stay ahead of the curve in an increasingly complex environment, SullivanCotter continues to innovate through its growing suite of technology, survey and data products. With Jeff’s specialized knowledge and expertise in business intelligence, data and information security, he will play a pivotal role in our risk-based approach to ensure the firm’s client-facing technology solutions remain highly effective, secure and compliant,” said David Schwietz, Chief Information Officer. Jeff works closely with clients to support compliance and assist with the way data is secured, managed and stored. He also directs SullivanCotter’s information security growth initiatives and resources internally to help drive greater value for clients. This includes establishing enterprise-level security initiatives, leading high-performing teams across a number of technical and analytical support areas, designing strategic information security policies, and auditing software and application vulnerability. Prior to joining SullivanCotter, Jeff spent more than 20 years with the Federal Reserve Bank of Minneapolis where he most recently served as the Information Security Officer. He also works as an adjunct professor and community faculty member at two Minneapolis-based technical colleges and universities to support higher education in information security and expand and develop local talent in this field. About SullivanCotter SullivanCotter partners with health care and other not-for-profit organizations to understand what drives performance and improve outcomes through the development and implementation of integrated workforce strategies. Using our time-tested methodologies and industry-leading research and information, we provide data-driven insights, expertise, data and technology to help organizations align business strategy and performance objectives – enabling our clients to deliver on their mission, vision and values. Contact Details Becky Lorentz +1 314-414-3719 beckylorentz@sullivancotter.com Company Website https://sullivancotter.com/

April 27, 2021 08:00 AM Eastern Daylight Time

Image

Kadimastem Raises NIS 22.3 Million ($6.8 Million) with a Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, has raised NIS 22.3 million ($6.8 million) in a private placement led by institutional investors Alpha Capital Anstalt and Clover Wolf Capital. As part of the agreement for their investment, participants received shares as well as NIS 31.1 million ($9 million) collectively in options. This brings this financing to a potential total of NIS 53.4 million ($16 million) collective investment. The financing will enable Kadimastem to expedite its research and development programs for both lead indications, AstroRx® for the treatment of ALS, and IsletRx, intended to cure Type 1 diabetes. The financing will also enable the company to advance its business development efforts in the US. Kadimastem CEO Asaf Shiloni said, “The financing announced is a clear demonstration of trust in Kadimastem’s new leadership team and its ability to lead the company to success, as well as in the company's technology and the capabilities of its talented scientific team. We believe that this investment will enable us to significantly advance the clinical development of our lead product candidates, which we anticipate could improve the quality of life of millions of patients worldwide.” Mr. Shiloni continued, “Kadimastem’s board of directors and management consider today’s news, an important step in achieving international recognition of its capabilities and the company's business plan." Kadimastem Chairman of the Board Ronen Twito said, “Today’s private placement is indicative of the strength of Kadimastem’s new leadership and the high quality of the company’s science, R&D and clinical programs. Alpha Capital Anstalt and Clover Wolf Capital are known for investing in leading and successful technology and specifically biotechnology companies. We would like to officially welcome them to the Kadimastem family.” About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Ltd. Asaf Shiloni +972 73-797-1613 a.shiloni@kadimastem.com Must Have Communications Marjie Hadad +19177901178 marjie@mhc-pr.com

April 26, 2021 07:00 AM Eastern Daylight Time

Image

WaveMAX Laundry and OMNI Solutions Make Waves Against COVID-19

OMNI Solutions, LLC

OMNI Solutions, the global leader in UV technology, and WaveMAX Laundry, the nation's largest, fastest-growing laundromat service provider, have partnered to bring consumers the first hospital-grade cleaning and disinfection laundromat franchise in the country. Serving as an essential business throughout the COVID-19 pandemic, WaveMAX looked for ways to improve and guarantee laundry disinfection to support front-line workers and everyday families trying to stay safe. While researching the benefits and costs of conventional ozone systems, WaveMAX found that OMNI Solutions' LUX UV system checked every box and more, far exceeding conventional ozone systems in cleaning, safety, disinfection, and eco-friendliness. "The WaveMAX Advantage elevates the laundromat visit from an inconvenient chore to a positive experience in a clean, safe, eco-friendly environment," says Michael Roberts, CEO of WaveMAX Laundry. "Now, with the addition of OMNI Solutions’ LUX UV system, it also provides the highest levels of clean and disinfection, including the ability to kill SARS-CoV-2." WaveMAX is disrupting the laundromat industry. 450 G-Force high-speed extraction washers allow a wash and dry in under an hour, giving precious time back to the consumer. All WaveMAX locations are impeccably maintained with a full-time attendant, a wash-dry-fold service, and free WiFi. The WaveMAX App enhances the experience with smartphone payment options and alerts for washer availability and cycle completion. The WaveMAX Advantage allows customers more time to focus on their lives and families, cutting hours from the laundry process. Proven and trusted Hospitals and health care facilities, such as the Mayo Clinic, trust OMNI Solutions' LUX UV laundry system over conventional disinfection procedures. OMNI's LUX UV system achieves the highest level of oxidation and disinfection in the laundry industry—far above hot water, bleach, and traditional ozone systems—reaching the highest level of clean and a hospital-grade 5-log 99.999% reduction in pathogens. LUX UV is the only system in the industry with a SARS-CoV-2 kill claim. It also destroys other disease-causing organisms such as C. diff, MRSA, and human coronavirus, all while disinfecting the wash drum, assuring a sterile washer for the next customer. In keeping with the WaveMAX Advantage, the LUX UV System significantly reduces natural gas, lowers hot and freshwater consumption, and shortens dry time - all of which provide environmental benefits that no other ozone system can equal. Unlike conventional ozone systems, the LUX UV system generates no toxic gas, has no motorized parts, requires no extra floor or wall space, and is easy to install. Maintenance is minimal, requiring only annual lamp replacement. Andrew Rupnow, chairman and CEO of OMNI Solutions, noted, "OMNI is proud to partner with WaveMAX to further the WaveMAX Advantage by providing a patented, eco-friendly, hospital-grade laundry system in support of front-line workers and families." Employing the best technology available nationwide, WaveMAX Laundry and OMNI Solutions deliver two priceless benefits to their customers – more time for life and family, and confidence in the hygienically clean linen they take home to their families. About WaveMAX Laundry: Based in Jacksonville, Florida, WaveMAX Laundry is the fastest-growing laundromat franchise of its kind. Since 2012, WaveMAX has been developing a scalable, state-of-the-art store model. With a focus on exceptional service and cutting-edge, eco-friendly technology, WaveMAX has improved the laundromat experience for its customers, providing peace of mind from the time they enter the laundromat until they arrive home to their families with the most hygienically clean laundry possible. The WaveMAX Advantage has elevated the industry standard. WaveMAX currently has more than 22 locations, with an additional 104 scheduled to open across the country by 2022. Visit WaveMAX Laundry at https://wavemaxlaundry.com. About OMNI Solutions: OMNI Solutions is an EPA-registered manufacturer of patented, earth-friendly, UV-based technologies for water, surface, and air treatment. Headquartered in Baraboo, Wisconsin, OMNI is revolutionizing the UV disinfection, commercial laundry, and water-processing industries with innovative, energy-efficient products. OMNI technologies are designed to maintain the highest standards of cleanliness, increase customers' profit margins through utility, water, and chemical savings, and improve the performance and quality of the cleaning process. With over 2,000 laundry installations processing more than 1 billion pounds per year, OMNI maintains its place as the world's largest supplier of UV laundry systems. For more information, contact OMNI Solutions at 1-888-356-9111 or visit https://www.omnisaves.com. Contact Details OMNI Solutions Russ Rankin +1 562-712-8958 rrankin@omnisaves.com Company Website https://www.omnisaves.com

April 22, 2021 11:17 AM Central Daylight Time

Centre for Neuro Skills and University of Texas Medical Branch Study Indicates That Chronic Traumatic Brain Injury Patients Are Not Absorbing Needed Nutrients

Centre for Neuro Skills

According to the Centers for Disease Control & Prevention, more than 2.5 million Americans suffer traumatic brain injuries (TBI) each year. A new and recent study, supported by the Centre of Neuro Skills in conjunction with the University of Texas Medical Branch at Galveston, found abnormal reactions between the brain and gastrointestinal tract (gut-brain axis) in moderate to severe chronic TBI patients. The result is that these patients may not be absorbing nutrients properly and treatments need to be developed to address these issues. The study was conducted at the University of Texas Medical Branch in the Department of Neurology in Galveston, Texas (under the supervision of Dr. Brent Masel) and the Centre of Neuro Skills in Bakersfield, California (under the supervision of Dr. Mark Ashley). Study Summary: The controlled study followed 10 TBI patients in Galveston, where Dr. Masel is a clinical professor at the University of Texas Medical Branch in the Department of Neurology. Dr. Masel is also the vice president of Medical Services at the Centre for Neuro Skills. Researchers had the patients fast, get their blood drawn, eat a specific meal and get their blood drawn again. TBI patients had low baseline levels of essential amino acids. Even after eating a meal, their levels remained lower than the non-injured study participants. Researchers determined that TBI patients weren’t absorbing essential amino acids. Dr. Masel and his colleagues made this determination and then wondered if it was simply the local diet or geographical location (lifestyle/exercise, stress, etc). He called Dr. Mark Ashley and suggested an identical study at the Centre for Neuro Skills in Bakersfield, California. The results were the same, so the conclusion was that this issue wasn’t related to diet, location or lifestyle. Dr. Masel’s observation: “The commonality is TBI. Essential amino acids are not being absorbed from the gut, and those molecules are critical to TBI recovery. This is amazing to me: maybe these patients are starving. I figured there must be a connection between the gut-brain axis.” After administering the fasting/eating/blood draw protocol, they added stool sample analysis. The study then focused on the microbiome and its relation to bacteria in the gut. The gut can say “OK” to a healthy system and absorb essential amino acids or can “gobble up” the same molecules depriving the human of using these critical nutrition components. That’s what was found in the fecal matter. Essential amino acids were missing; the commonality in both the Texas and California groups was TBI. This may affect the ability of patients to fully recover. In CNS’ “whole person” approach, it could affect the quality of functionality/return to normalcy. Point of distinction here – with CNS’ dedicated research team, these discoveries/research/scientists and their publications can advance treatment and expand understanding of the depth of TBI’s damage. The study’s distinction is that the two groups, thousands of miles apart, produced the same outcome and the same deficit of non-absorption. The CNS patient study group was part of CNS’ Long Term Care program, so the organization will be able to study them now and in the future. Observations: “Clearly there are abnormalities in the microbiome of the gut in TBI patients,” commented Dr. Masel. “Maybe this is a piece of the puzzle that can solve the mystery of TBI. It’s one puzzle piece at a time. Presently, the majority of what we do is treat the symptoms of TBI, as opposed to the underlying causes of those symptoms, which would be far more effective. Perhaps by correcting the malabsorption of the essential amino acids, we can advance the recovery from TBIs. We will be studying how altering the diet in these individuals may change their amino acid absorption. Our hope is that this will assist in identifying long-term risks and treatments.” Comments CNS’ Dr. Ashley, “It’s gratifying to be part of a study that in the end may help identify keys that allow us to better treat patients with TBI for the long haul. With CNS’ dedicated research team and these discoveries, we hopefully can advance treatment and expand our understanding of the depth of TBI’s damage. We look forward to the next steps.” This study was funded by the Moody Endowment (funding M.S.M.) and conducted with the support of TideWay, part of the Transitional Learning Center (Galveston, TX) and the Centre for Neuro Skills (Bakersfield, CA). The study took place with 8 patients in Galveston and 12 patients in California. The link to the full study is here. About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: https://www.neuroskills.com/, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit: https://youtu.be/Jwqve9gWtEw. About University of Texas Medical Branch The Department of Neurology at the University of Texas Medical Branch (UTMB) was established in 1973. It has a long-standing history and tradition in the practice and advancement of Clinical Neurosciences by providing the most comprehensive care to patients with neurologic illnesses from Alzheimerâs disease and related dementias, epilepsy, neuromuscular disorders, brain tumors, Parkinsonâs Disease and other movement disorders, multiple sclerosis and other autoimmune disorders, stroke as well as other acute neurologic injuries. For more information, visit: https://www.utmb.edu/neuro. Editors, please note: Photos, videos and interviews are available by contacting Robin Carr at (415) 971-3991 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 cns@landispr.com Company Website https://landispr.com/

April 21, 2021 10:27 AM Pacific Daylight Time

CIPIO Completes $2M in Pre-seed funding to launch Industry's First Domain Infused Data Apps Platform™ for the B2C Subscription Businesses

CIPIO.ai

CIPIO, a B2C Subscription Customer Success company, today announced the launch of the Industry's first Domain Infused Data Apps Platform™ that solves the massive business problem of retention and growth. Amidst the unprecedented disruption and digital acceleration triggered by COVID-19, this problem has multiplied by ten folds as customer behavior, decision making, and choices have changed dramatically. To accelerate its growth and product innovation, CIPIO completed its $2M pre-seed round in December 2020, led by DX.Partners and an experienced team of investors- including Linda Abraham, Managing Partner of Crimson Capital, Vineet Goel of Visa, Kathy Holmes of Arcola Investment, Ketan Karkhanis CPO of Turvo (ex-Salesforce GM & SVP), Karl Rumelhart, CPO of Gainsight, and the Dean of Big Data-Bill Schmarzo. CIPIO disrupts the B2C Subscription Customer Success category by unifying vast quantities of data from systems of records, customer behavior, and domain infused pre-built data apps. Companies get actionable predictions and recommendations that are directly integrated into engagement systems such as Hubspot to ensure maximum financial outcomes. Gartner predicts that 75% of B2C Businesses will offer Subscription services by the year 2023. "COVID-19 has hyper accelerated this transform across Fitness, OTT, Sports, Entertainment & Media just to name a few. Yet B2C Subscriber churn is 3X the churn in the B2B SaaS market, and B2C Growth rate is 50% lower than the B2B Saas Companies," says Growson Edwards, Co-Founder & CEO of CIPIO. "At CIPIO, we understand the change and disruption B2C Subscription Businesses are facing in this new Hybrid Subscription Economy and are desirous about our mission to help our customers Retain, Grow, and Acquire their subscribers exponentially." "CIPIO's domain centric approach to address the significant gap in today's CDP solution is a game changer. Data Apps are the future of the Hybrid Subscription Economy, and CIPIO's Retention, Growth, and Acquisition Data Apps are directly and rapidly impacting the customer's bottom line," said Ketan Karkhanis, Chief Product Officer at Turvo, and an investor at CIPIO. Ketan previously ran Einstein Analytics at Salesforce and has in depth experience with Customer Success in the B2B SaaS market. “As founders, we are channeling our B2B SaaS Retention & Growth knowhow into our Domain infused Data Apps Platform™ for B2C SaaS,” says Manoj Kumar Goyal, Co-Founder & CPO of CIPIO. Mr. Goyal previously led Oracle’s Customer Data Platform team, served as Marketo’s Chief Product Officer, and is obsessed with delivering ROI. “We are removing 8-12 months of the time and a myriad of domain experts, BI specialists, Data Engineers, and Data Scientists it takes to generate value out of Customer data.” continues Goyal. “Our Data Apps are powered by Domain infused AI Platform that automates all the necessary functions to generate value out of Data with efficient Human Involvement built specifically for our customer.” The company is so confident in delivering the ROI so much that they are giving away their Domain Infused Data Apps Platform™ for free until the customer sees the results of acceleration in retention, growth, and acquisition. Companies can access the Industry's first Domain Infused Data Apps free trial here. About CIPIO: CIPIO is pioneering the Industry's first domain-infused Data Apps Platformâ¢ that humanizes and automates predictions and recommendations to increase Subscriber engagement, retention, and growth for B2C Businesses. CIPIO's early adopters include Crunch Fitness, Industry's Gym, Xponential Fitness, Motor City Church, Pure Barre, Club Pilates, AKT, YogaSix, NCFit, Cyclebar, RowHouse, Stretch Lab, and Stride who have witnessed a significant return on investment in a short time. Contact Details CIPIO Chris Foudy +1 831-238-1905 chris@cipio.ai Company Website https://cipio.ai/

April 21, 2021 12:15 PM Eastern Daylight Time

SullivanCotter Releases Comprehensive APP Utilization and Perceptions Manager for its Growing Benchmarks360™ Platform

SullivanCotter

SullivanCotter, the nation’s leading independent consulting firm in the assessment and development of total rewards programs, workforce solutions, and technology and data products for the health care industry and not-for-profit sector, is pleased to announce the addition of powerful new capabilities for assessing advanced practice provider (APP) utilization and workforce perceptions to its growing Benchmarks360™ platform. Powered by SullivanCotter’s proprietary surveys and research, Benchmarks360™ is a suite of intelligent, web-based products that enables health care organizations to analyze and visualize compensation, clinical productivity and workforce perceptions through industry-leading data, analyses and reporting. "In today's unprecedented health care environment, it is important for organizations to utilize, engage and retain their clinical workforce more effectively. APP turnover can significantly impact cost, morale and operations, and gaining access to the right data and benchmarking tools can help to enhance workforce retention, team-based care practices and organizational performance during such a critical time,” said Amy Noecker, APP Workforce Practice Leader, SullivanCotter. SullivanCotter’s Benchmarks360™ APP Utilization and Perceptions Manager allows organizations to collect, benchmark and report on the thoughts and experiences of their APPs and physicians related to APP compensation, resources and job responsibilities to help ensure current pay programs and care models are competitive and effective. In addition to data on nurse practitioners and physician assistants, it also provides information and analysis on other members of the APP workforce including certified registered nurse anesthetists and certified nurse midwives. This new module includes two surveys designed to measure and compare individual organizations to national benchmarks. APP: Utilization and Perceptions Survey Learn more about the APP employment experience within your organization regarding scope of practice, clinical and non-clinical responsibilities, and perceptions on culture and compensation. Specific insights include: Organizational structure, support and processes related to the APP workforce Roles on the care team specific to location and specialty Degree of integration and care team support Opportunities for improved utilization and engagement Physician: APP Utilization and Perceptions Survey Learn more about your physician workforce and their experience working with APPs. Specific insights include: Perception on APP integration and utilization Roles of APPs on the care team APP impact on quality, access and patient engagement Understanding of regulatory requirements Opportunities for improved alignment and team performance These surveys may serve as a resource for organizations looking to better understand the current state of their APP workforce – including quantifying opportunities for optimization and readiness for change – and can play an important part in a more holistic review of APP practices when combined with SullivanCotter’s comprehensive advisory services. “As health care organizations continue to navigate the lasting effects of a global pandemic, SullivanCotter remains committed to providing them with the critical, data-driven insights they need to measure, analyze and report on compensation and workforce performance. With the goal of addressing the increasingly complex and evolving needs of our clients, we are developing one of the industry’s most comprehensive benchmarking solutions by continuously refining our product roadmap and adding innovative new resources and functionality,” said David Schwietz, Chief Information Officer, SullivanCotter. To learn more about Benchmarks360™, including important licensing information and a full list of features and functionality, visit sullivancotter.com/benchmarks360 or call 888.739.7039. About SullivanCotter SullivanCotter partners with health care and other not-for-profit organizations to understand what drives performance and improve outcomes through the development and implementation of integrated workforce strategies. Using our time-tested methodologies and industry-leading research and information, we provide data-driven insights, expertise, data and technology products to help organizations align business strategy and performance objectives – enabling our clients to deliver on their mission, vision and values. Contact Details Becky Lorentz +1 314-414-3719 beckylorentz@sullivancotter.com Company Website https://sullivancotter.com/

April 21, 2021 08:00 AM Eastern Daylight Time

Industrial Defender ASM for Splunk App Delivers Deeper Contextual Data for Faster Response to Security Events

Industrial Defender

Industrial Defender, a pioneer in operational technology (OT) security, today announced the launch of their Industrial Defender ASM for Splunk App in Splunkbase. When a security event occurs in complex OT environments, it can be difficult to get the right information to the right people to quickly respond to an emerging cybersecurity threat. The Industrial Defender ASM for Splunk app solves this challenge by delivering security events with deep asset context to analysts, so they can quickly identify and mitigate potential security issues. “This app is unique within the OT space because it goes beyond simply providing basic alert data from the network. It also delivers contextual asset data, like vulnerabilities, changes to firewall rules, user accounts, and use of removable media, along with the location, criticality, and contact information for the OT asset owner, directly to security analysts,” says Peter Lund, VP of Product Management at Industrial Defender. “With this app, security operations teams will have a much easier time identifying and diagnosing a real cybersecurity issue versus an operational change. By enhancing collaboration between IT and OT teams, the app will help our customers get the most value out of their investments in both Splunk and the ASM.” The Industrial Defender ASM for Splunk app delivers detailed asset and network data related to security events and changes into two pre-configured dashboards, the SOC Dashboard and the Asset Insights Dashboard. The API Add-on also automates the manual process of mapping the comprehensive data sets provided by the ASM to the Splunk user interface. To preview all the asset and security data that the Industrial Defender ASM for Splunk App provides, view the solution brief or download the app in Splunkbase. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. Contact Details Industrial Defender Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

April 20, 2021 09:07 AM Eastern Daylight Time

D8 Holdings to Accept Bitcoin, Ethereum, Dogecoin for Delta-8 THC Products

D8 Holdings, Inc.

D8 Holdings, Inc., the market leader in hemp-derived Delta-8 THC —today announced it will start accepting Bitcoin, Ethereum and Dogecoin as payment methods on their site. “Our customers are early adopters, many of whom are heavily involved in the crypto market,” said Chris Duffield, CEO of D8. “With $2 trillion dollars sitting in crypto assets, and $45 billion parked in Dogecoin, the ability to accept crypto currency presents a big opportunity for our company.” D8.co will integrate Bitpay into their online platform, and all transactions will be settled in Doge. With the click of a button, customers can trade Doge for delta-8 gummies, delta-8 carts and delta-8 disposables as long as they are over 21 years of age. “Anyone paying with crypto will get a free pack of Delta-8 gummies as a bonus. We are looking long-term, and don’t plan on selling a single Doge,” concluded Duffield. About D8 Holdings Inc. The D8 Holdings team based in Colorado and Miami—with satellite offices in Las Vegas and Los Angeles—is an assembly of the top hemp and cannabis minds in the country. With backgrounds in extraction, chemistry, manufacturing, marketing, distribution, and legal, the D8 Holdings team came together organically around this elusive, but extremely powerful molecule to create a new category of products. More info at www.d8.co. # # # Contact Details D8 Holdings Chris Duffield +1 424-333-2112 chris@d8.co

April 20, 2021 08:30 AM Eastern Daylight Time

Healthcare